BHCM
AMLX icon

Brevan Howard Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Brevan Howard Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
+11,611
New +$180K ﹤0.01% 1885
2025
Q4 		– Sell
-56,667
Closed -$770K – 1753
2025
Q3 		$770K Buy
+56,667
New +$533K ﹤0.01% 1031
2025
Q2 		– Sell
-11,330
Closed -$40.1K – 1831
2025
Q1 		$40.1K Buy
+11,330
New +$40.3K ﹤0.01% 1100
2024
Q1 		– Sell
-53,517
Closed -$788K – 994
2023
Q4 		$788K Buy
+53,517
New +$820K 0.01% 310

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Brevan Howard Capital Management's AMLX Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 11,611 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #1885 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in AMLX as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in AMLX in Q4 2023 and has held it in 4 quarters since. The position peaked at $788K in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Brevan Howard Capital Management held 11,611 shares of Amylyx Pharmaceuticals worth $209K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Brevan Howard Capital Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1885 holding.
  • Brevan Howard Capital Management first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Amylyx Pharmaceuticals position peaked at $788K in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.